thumbnail image
broken image
broken image

 

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
  • Publication
  • Newsroom
  • Get in Touch
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
    • Publication
    • Newsroom
    • Get in Touch
    broken image
    broken image

     

    seek and you will find

    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
    • Publication
    • Newsroom
    • Get in Touch
    • …  
      • Home
      • Technology
      • Products 
        • Products Overview
        • SeekInCare
        • SeekInCure
        • SeekInClarity
        • OncoSeek
        • LeukoPrint
      • Publication
      • Newsroom
      • Get in Touch
      broken image
      • SeekInCure®

        The first-in-class blood-based pan-cancer recurrence monitoring test

        broken image

        SeekInCure® is applied to monitoring cancer recurrence and risk evaluation for post-op cancer patients. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer patients continually, combined with plasma protein markers, equipping big data and artificial intelligence, it generates cancer recurrence index (CRI) .

        broken image
      • A panoramic view of cancer genomic landscape

        cfDNA detection via NGS drawing the view of cancer genomic landscape

        Cutting-edge multivariate algorithm

        Genomics combined with proteomics,capturing the signal of cancer recurrence

        Multidimensional fingerprint

        CNA, Fragmentation and protein markers discovering the early cancer recurrence

        Big date and Artificial intelligence

        CRI model based on machine learning evaluating the risk of cancer recurrence precisely

      • broken image
      • Specifications

        ◉ Indicated subjects: post-surgery cancer patients

        ◉ Sample requirement: 10ml peripheral blood

        ◉ Result readout: CRI (cancer recurrence index)

        ◉ TAT: 10 working days

         

        Sampling time:

        broken image
      •  

        How it works

        broken image

        Pre-test inquiry

         

        broken image

        Informed consent 

        broken image

        Blood-draw

        broken image

        Testing

        broken image

        Analyzing + Interpretation

         

        broken image

        Reporting

         

      Navigation

      Home

      Technology   

      SeekInCare

      SeeInCure

      SeekInClarity

      OncoSeek

      Publication

      Contact Us

      10320 Camino Santa Fe, Suite G

      San Diego, CA 92121

      United States

      info@seekincancer.com

      © 2023 SeekIn, Inc.

      All Rights Reserved.

      All Posts
      ×
      Cookie Use
      We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
      Learn More